For patients with metastatic pancreatic cancer, Rasonque has shown it can double survival rates. The US Food and Drug Administration has now approved the oral medication from Revolution Medicines. The decision follows results from a large clinical trial. Based on daraxonrasib, the drug is intended for daily use by patients who have undergone previous treatments or cannot receive combination chemotherapy.
Rasonque works by blocking multiple forms of the RAS protein, a basic driver of tumor growth in pancreatic cancer. Revolution Medicines has set the price at $39,800 for a 30-day supply in the United States, prompting questions about affordability and insurance coverage. The company says it will provide assistance programs for eligible patients. When the clinical trial results were first announced in April, demand for the drug surged. The FDA then granted early access through its compassionate use program. Some patients began treatment before full regulatory approval, and several reported relief from chemotherapy's harsh side effects.
The FDA approved the drug through its accelerated review pathway, which has shortened the typical timeline from nearly a year to a few months for certain breakthrough therapies. Revolution Medicines CEO Mark Goldsmith described the approval as the culmination of more than a decade of research into RAS-driven pancreatic cancer, long considered one of oncology's most challenging areas.
Investor interest in Revolution Medicines has soared, with the company's stock rising 166% since the start of the year. Analysts project that Rasonque could eventually generate up to $11.5 billion in annual global sales. The American Cancer Society expects approximately 67,350 new cases of pancreatic cancer to be diagnosed in the US this year, underscoring the need for more effective treatments.
Access to new therapies remains a major healthcare issue. In Spain, for example, delays in public hospital treatment have led many patients to seek private care, as highlighted in a recent report on rising surgical waiting lists in Madrid. The introduction of high-cost drugs like Rasonque raises questions about how health systems will manage demand and equitable access, especially as new therapies arrive at premium prices.
Pancreatic cancer has a poor prognosis and limited treatment options, with most cases diagnosed at an advanced stage. Rasonque is a rare advance in a field where progress has been slow. Its high cost and the challenge of integrating such therapies into public health systems remain unresolved. As more breakthrough drugs reach the market, debate over pricing and access, as well as oncology's long-term sustainability, is likely to intensify in the US and across Europe.
